接受抗逆转录病毒药物和聚乙二醇化干扰素α治疗的原发性HIV-1感染中HIV复制的早期控制：Primoferon A（ANRS 086）研究结果
Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study.
作者信息
Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, Rudent A, Molina J M, Livrozet J M, Souala F, Chene G, Grangeot-Keros L, Galanaud P, Sereni D, Rouzioux C
机构信息
Service de Médecine Interne et d'Immunologie Clinique, Hôpital Antoine Béclère, Institut Paris-Sud sur les Cytokines, Clamart, France.
出版信息
AIDS. 2001 Jul 27;15(11):1435-7. doi: 10.1097/00002030-200107270-00014.
IFN alpha has both antiviral and immunostimulating properties. The ANRS086 Primoferon A Study evaluated in 12 patients with primary HIV infection the tolerance and efficacy of an early and transient administration of pegylated IFN alpha, in addition to highly active antiretroviral therapy. Tolerance was good, and this regimen allowed the early control of HIV replication and rapid decay of the viral reservoir. These results support the initiation of comparative studies with pegylated INF alpha in primary HIV infection.
干扰素α具有抗病毒和免疫刺激特性。ANRS086普里莫费龙A研究评估了12例原发性HIV感染患者在接受高效抗逆转录病毒治疗的同时，早期短暂使用聚乙二醇化干扰素α的耐受性和疗效。耐受性良好，该方案可使HIV复制得到早期控制，病毒储存库迅速衰减。这些结果支持在原发性HIV感染中开展聚乙二醇化干扰素α的比较研究。
Zotero 插件